Replies to post #48764 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

NWBO and regulators need to conduct simple division.

13,000 / 365 = 36 (see below)

The A team of lab techs that worked on the phase III L trial in Memphis and Germany are now available for commercialization in my opinion.

NWBO eventually needs to average 36 batches per day in the United States if they corner the U.S.A. GBM market. That adds up to 13,000 per year. Since Cognate said back in July the building expansion would be done about now, and they will ramp up to, if I recall, 80 additional employees by summer, I see them capable of handling any potential transition to DCVax-L very soon. JMHO.

The ramp will no doubt occur, because there are only so many hospitals trained to follow the protocol the correct way at this time. So it is a natural transitional period. Other Hospitals, if the results are strong, would be clamoring to understand the "new" system, (preserving tumor, transfer of tumor material, receipt of tumor material, thawing and proper two arm intradermal injections), but that transition will create a natural ramp allowing NWBO to handle the increase in 2016. IMHO.